The Comprehensive Genetic Test for Short QT Syndrome (SQTS) utilizes next-generation sequencing (NGS) to examine 5 genes associated with short QT syndrome and cardiac ion channel disorders, It is a targeted gene panel specifically designed to support accurate diagnosis, risk assessment, and prevention.
More Information
The Comprehensive Genetic Test for Short QT Syndrome (SQTS) is a targeted genetic test designed to evaluate hereditary causes of short QT syndrome, a rare cardiac channelopathy affecting the electrical activity of the heart. The comprehensive genetic test for short QT syndrome (SQTS) includes the analysis of 5 genes, along with selected non-coding variants, enabling a focused assessment of genetic factors associated with this condition. It is primarily used in individuals with a clinical suspicion of short QT syndrome based on electrocardiographic findings and clinical presentation. This disorder is characterized by abnormally accelerated cardiac repolarization, which predisposes to life-threatening arrhythmias and sudden cardiac events in structurally normal hearts.
The comprehensive genetic test for short QT syndrome (SQTS) includes key genes such as KCNH2, KCNQ1, KCNJ2, CACNA1C, and CACNB2, which are involved in cardiac ion channel function and regulation of repolarization. These genes encode potassium and calcium channels that control the duration of the cardiac action potential. Proper ion flow is essential for maintaining normal cardiac rhythm and electrical stability. Alterations in these channels lead to shortened repolarization phases and increased susceptibility to arrhythmias. The comprehensive genetic test for short QT syndrome (SQTS) is indicated in individuals with a shortened QT interval on ECG and clinical features suggestive of short QT syndrome.
The clinical spectrum of short QT syndrome (SQTS) is variable and includes atrial and ventricular tachyarrhythmias, syncope, palpitations, and sudden cardiac death. Cardiac arrest is the most commonly reported manifestation and may occur as the first clinical event in a significant proportion of patients. The condition can present at any age, including infancy, and has been proposed as a potential cause of sudden infant death syndrome. Some individuals may remain asymptomatic, while others present with severe arrhythmic events. Diagnosis is typically based on clinical history, electrocardiographic findings, and family history, with considerable variability in disease expression.
The purpose of the comprehensive genetic test for short QT syndrome (SQTS) is to identify pathogenic variants associated with short QT syndrome, supporting accurate diagnosis and differentiation from other inherited arrhythmia disorders. Genetic findings contribute to improved understanding of the molecular mechanisms underlying accelerated cardiac repolarization and support appropriate disease classification. The identification of specific genetic alterations assists in risk assessment, prognosis evaluation, and the development of individualized long-term monitoring strategies.
A higher genetic risk is confirmed when pathogenic mutations are found in genes associated with short QT syndrome, including KCNH2, KCNQ1, and KCNJ2. A lower risk may be inferred when no mutations are detected, though comprehensive clinical follow-up is still essential. The integration of genetic data with clinical findings and electrocardiographic evaluation is critical for precise diagnosis, prognosis, and long-term patient care.
The test is performed in a clinical laboratory accredited to ISO 15189 and certified by CLIA and CAP, ensuring the validity, accuracy and international recognition of the results.
